148 related articles for article (PubMed ID: 17728187)
1. CpG oligodeoxynucleotides induce cyclooxygenase-2 in human B lymphocytes: implications for adjuvant activity and antibody production.
Bernard MP; Phipps RP
Clin Immunol; 2007 Nov; 125(2):138-48. PubMed ID: 17728187
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens.
Kovarik J; Bozzotti P; Tougne C; Davis HL; Lambert PH; Krieg AM; Siegrist CA
Immunology; 2001 Jan; 102(1):67-76. PubMed ID: 11168639
[TBL] [Abstract][Full Text] [Related]
3. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
[TBL] [Abstract][Full Text] [Related]
4. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.
Zhang Y; Palmer GH; Abbott JR; Howard CJ; Hope JC; Brown WC
Vaccine; 2003 Jul; 21(23):3307-18. PubMed ID: 12804862
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM
Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
[TBL] [Abstract][Full Text] [Related]
6. Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.
Bohle B; Orel L; Kraft D; Ebner C
J Immunol; 2001 Mar; 166(6):3743-8. PubMed ID: 11238615
[TBL] [Abstract][Full Text] [Related]
7. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
8. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
9. CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.
Chen Y; Zhang J; Moore SA; Ballas ZK; Portanova JP; Krieg AM; Berg DJ
Int Immunol; 2001 Aug; 13(8):1013-20. PubMed ID: 11470771
[TBL] [Abstract][Full Text] [Related]
10. Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step.
Macfarlane DE; Manzel L; Krieg AM
Immunology; 1997 Aug; 91(4):586-93. PubMed ID: 9378499
[TBL] [Abstract][Full Text] [Related]
11. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.
Brummel R; Lenert P
J Immunol; 2005 Feb; 174(4):2429-34. PubMed ID: 15699180
[TBL] [Abstract][Full Text] [Related]
12. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production.
Ryan EP; Pollock SJ; Murant TI; Bernstein SH; Felgar RE; Phipps RP
J Immunol; 2005 Mar; 174(5):2619-26. PubMed ID: 15728468
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
[TBL] [Abstract][Full Text] [Related]
14. COX-2 expression in B lymphocytes: links to vaccines, inflammation and malignancy.
Mongini PK
Clin Immunol; 2007 Nov; 125(2):117-9. PubMed ID: 17869184
[No Abstract] [Full Text] [Related]
15. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
Li WM; Bally MB; Schutze-Redelmeier MP
Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
[TBL] [Abstract][Full Text] [Related]
16. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells.
Ryan EP; Pollock SJ; Kaur K; Felgar RE; Bernstein SH; Chiorazzi N; Phipps RP
Clin Immunol; 2006 Jul; 120(1):76-90. PubMed ID: 16473553
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
18. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
19. Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages.
Ghosh DK; Misukonis MA; Reich C; Pisetsky DS; Weinberg JB
Infect Immun; 2001 Dec; 69(12):7703-10. PubMed ID: 11705951
[TBL] [Abstract][Full Text] [Related]
20. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T; Peschel C
Leuk Lymphoma; 2001 Jul; 42(3):301-7. PubMed ID: 11699394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
